{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:01Z","timestamp":1791327421975,"version":"4.3.1"},"reference-count":32,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GWT-TUD GmbH, Dresden, Germany"},{"name":"Baxalta Innovations GmbH"},{"name":"Takeda Pharmaceuticals International AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The Facilitated Immunoglobulin Administration Registry And Outcomes (FIGARO) Study was a European, multicenter, prospective, observational study conducted across Europe designed to provide insights on the clinical use and tolerability of facilitated subcutaneous immunoglobulin (fSCIG). Data herein are reported for the cohort of patients with secondary immunodeficiency (SID), with a subgroup analysis by age. The SID cohort included 31 patients: 1 pediatric, 15 adult, and 15 older adult patients. Over the 36-month observation period, the median monthly dose of fSCIG (30 g) and median monthly infusion volume per patient (300 mL) remained constant in both adult-age cohorts. Serum trough levels tended to increase over time. Most patients required only one infusion site and could receive the full dose every 3\u20134 weeks. There was a trend toward self-administration at home. In the adult group, infusion site inflammation and headache were reported at the inclusion visit (n = 1 each), with no adverse drug reactions reported at any of the follow-up visits. No acute severe bacterial infections were reported during the study follow-up. These results demonstrate the feasibility and tolerability of fSCIG use in patients with SID and the flexibility of administration settings including self-administration at home in patients aged \u226565 years.<\/jats:p>","DOI":"10.3390\/cancers15184524","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:41:12Z","timestamp":1694554872000},"page":"4524","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8197-9895","authenticated-orcid":false,"given":"Maria","family":"Dimou","sequence":"first","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine, National & Kapodistrian University of Athens Medical School, General Hospital \u201cLAIKO\u201d, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1287-7734","authenticated-orcid":false,"given":"Matthaios","family":"Speletas","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Department of Immunology and Histocompatibility, Faculty of Medicine, University of Thessaly, GR-41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-9250","authenticated-orcid":false,"given":"Cinzia","family":"Milito","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pyzik","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Center of Oncology St. Jana, 20-090 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-0761","authenticated-orcid":false,"given":"D\u00f6rte","family":"Huscher","sequence":"additional","affiliation":[{"name":"Institute of Biometry and Clinical Epidemiology, Berlin Institute of Health, Charit\u00e9-Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9931-2228","authenticated-orcid":false,"given":"Marta","family":"Kamieniak","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-2616","authenticated-orcid":false,"given":"David","family":"Pittrow","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacology, Medical Faculty, Technical University of Dresden, 01307 Dresden, Germany"},{"name":"Innovation Center Real World Evidence, GWT-TUD GmbH, 01067 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borte","sequence":"additional","affiliation":[{"name":"Hospital for Children and Adolescents, St. Georg Hospital, Academic Teaching Hospital of the University of Leipzig, IDCL (ImmunoDeficiency Center Leipzig), 04129 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: Causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Duraisingham, S.S., Buckland, M., Dempster, J., Lorenzo, L., Grigoriadou, S., and Longhurst, H.J. (2014). Primary vs. secondary antibody deficiency: Clinical features and infection outcomes of immunoglobulin replacement. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100324"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.anai.2021.08.413","article-title":"Secondary immunodeficiencies: An overview","volume":"127","author":"Tuano","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency\u2014Causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/1744666X.2016.1183482","article-title":"Facilitated subcutaneous immunoglobulin administration (fSCIg): A new treatment option for patients with secondary immune deficiencies","volume":"12","author":"Blau","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/10428194.2021.1992761","article-title":"Risk factors for severe infections in secondary immunodeficiency: A retrospective US administrative claims study in patients with hematological malignancies","volume":"63","author":"Jolles","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: A practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-3-319-77674-3_17","article-title":"Role of immunoglobulin therapy to prevent and treat infections","volume":"19","author":"Katragkou","year":"2018","journal-title":"Manag. Infect. Immunocompromised Host"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10875-023-01470-2","article-title":"Facilitated subcutaneous immunoglobulin treatment in patients with immunodeficiencies: The FIGARO study","volume":"43","author":"Borte","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/SMJ.0b013e3181eba6ea","article-title":"Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G","volume":"103","author":"Berger","year":"2010","journal-title":"South. Med. J."},{"key":"ref_13","first-page":"S98","article-title":"Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin","volume":"25","author":"Ness","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/imt-2017-0092","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases","volume":"9","author":"Wasserman","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/1744666X.2020.1807328","article-title":"A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants","volume":"16","author":"Bonet","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency\u2014An expert opinion","volume":"12","author":"Agostini","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/ITT.S31136","article-title":"Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency","volume":"2","author":"Jolles","year":"2013","journal-title":"Immunotargets Ther."},{"key":"ref_18","unstructured":"(2023, June 06). European Public Assessment Report (EPAR). HyQvia Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hyqvia-epar-product-information_en.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","article-title":"A recombinant human enzyme for enhanced interstitial transport of therapeutics","volume":"114","author":"Bookbinder","year":"2006","journal-title":"J. Control. Release"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10875-016-0298-x","article-title":"Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency","volume":"36","author":"Wasserman","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10875-011-9512-z","article-title":"Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease","volume":"31","author":"Wasserman","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/imt-2016-0066","article-title":"Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: Long-term efficacy, safety and tolerability","volume":"8","author":"Wasserman","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ejh.12900","article-title":"Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study","volume":"99","author":"Reiser","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/1744666X.2021.1913122","article-title":"Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: Poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies","volume":"17","author":"Borte","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_27","unstructured":"Health Quality Ontario (2017). Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment. Ont. Health Technol. Assess. Ser., 17, 1\u201386."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cei.12694","article-title":"Facilitated subcutaneous immunoglobulin (fSCIg) therapy\u2013practical considerations","volume":"182","author":"Ponsford","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.21873\/anticanres.12712","article-title":"Efficacy-safety of facilitated subcutaneous immunoglobulin in immunodeficiency due to hematological malignancies. A single-center retrospective analysis","volume":"38","author":"Dimou","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1111\/jocn.14580","article-title":"\u201cExperiences of the burden of treatment\u201d\u2014Patient reports of facilitated subcutaneous immunoglobulin treatment in adults with immunodeficiency","volume":"27","author":"Petersson","year":"2018","journal-title":"J. Clin. Nurs."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: A single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109331","DOI":"10.1016\/j.intimp.2022.109331","article-title":"Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies","volume":"113","author":"Li","year":"2022","journal-title":"Int. Immunopharmacol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4524\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:49:26Z","timestamp":1760129366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":32,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15184524"],"URL":"https:\/\/doi.org\/10.3390\/cancers15184524","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]}}}